Merck & Co., Inc. MRK

148.78 0.80 0.54% as of 25 Sep
Market cap
$365.4B
P/E
119×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Merck & Co., Inc. (MRK) P/S ratio

As of 25 September 2026, Merck & Co., Inc. (MRK) trades at a P/S ratio of 5.5×. Over the past ten years it has ranged from 2.9× (May 2025) to 5.8× (August 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 4.1× 3.20%
FY2024 3.9× (17.86%)
FY2023 4.8× 0.68%
FY2022 4.7× 19.23%
FY2021 4.0× (16.29%)
FY2020 4.8× (16.41%)
FY2019 5.7× 23.90%
FY2018 4.6× 25.80%
FY2017 3.7× (8.47%)
FY2016 4.0× 11.00%

Quarterly

Period P/S ratio Change
Jun 2026 4.8× 5.45%
Mar 2026 4.5× 11.61%
Dec 2025 4.1× 24.26%
Sep 2025 3.3× 4.38%
42 more quarters

Against its own ten years

Low 2.9× High 5.8×
Ten-year median 4.3×
Current reading's percentile 99

P/S ratio against peers

Company P/S ratio
PFE Pfizer Inc. compare 2.6×
NVO Novo Nordisk A/S compare 3.3×
AZN AstraZeneca PLC compare 4.2×
NVS Novartis AG compare 4.9×
MRK Merck & Co., Inc. 5.5×
AMGN Amgen Inc. compare 5.9×
GILD Gilead Sciences, Inc. compare 6.2×
JNJ Johnson & Johnson compare 6.7×
ABBV AbbVie Inc. compare 7.3×
Drug Manufacturers General industry median 3.3×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on MRK